332 related articles for article (PubMed ID: 26209241)
1. Aspirin provocation increases 8-iso-PGE2 in exhaled breath condensate of aspirin-hypersensitive asthmatics.
Mastalerz L; Januszek R; Kaszuba M; Wójcik K; Celejewska-Wójcik N; Gielicz A; Plutecka H; Oleś K; Stręk P; Sanak M
Prostaglandins Other Lipid Mediat; 2015 Sep; 121(Pt B):163-9. PubMed ID: 26209241
[TBL] [Abstract][Full Text] [Related]
2. Induced sputum eicosanoids during aspirin bronchial challenge of asthmatic patients with aspirin hypersensitivity.
Mastalerz L; Celejewska-Wójcik N; Wójcik K; Gielicz A; Januszek R; Cholewa A; Stręk P; Sanak M
Allergy; 2014 Nov; 69(11):1550-9. PubMed ID: 25123806
[TBL] [Abstract][Full Text] [Related]
3. Prostaglandin E
Mastalerz L; Tyrak KE; Ignacak M; Konduracka E; Mejza F; Ćmiel A; Buczek M; Kot A; Oleś K; Sanak M
Allergy; 2019 May; 74(5):922-932. PubMed ID: 30446997
[TBL] [Abstract][Full Text] [Related]
4. Inhaled PGE2 prevents aspirin-induced bronchoconstriction and urinary LTE4 excretion in aspirin-sensitive asthma.
Sestini P; Armetti L; Gambaro G; Pieroni MG; Refini RM; Sala A; Vaghi A; Folco GC; Bianco S; Robuschi M
Am J Respir Crit Care Med; 1996 Feb; 153(2):572-5. PubMed ID: 8564100
[TBL] [Abstract][Full Text] [Related]
5. Exhaled eicosanoids following oral aspirin challenge in asthmatic patients.
Sanak M; Kiełbasa B; Bochenek G; Szczeklik A
Clin Exp Allergy; 2004 Dec; 34(12):1899-904. PubMed ID: 15663565
[TBL] [Abstract][Full Text] [Related]
6. Increased exhaled cysteinyl-leukotrienes and 8-isoprostane in aspirin-induced asthma.
Antczak A; Montuschi P; Kharitonov S; Gorski P; Barnes PJ
Am J Respir Crit Care Med; 2002 Aug; 166(3):301-6. PubMed ID: 12153961
[TBL] [Abstract][Full Text] [Related]
7. Cromolyn sodium prevents bronchoconstriction and urinary LTE4 excretion in aspirin-induced asthma.
Yoshida S; Amayasu H; Sakamoto H; Onuma K; Shoji T; Nakagawa H; Tajima T
Ann Allergy Asthma Immunol; 1998 Feb; 80(2):171-6. PubMed ID: 9494450
[TBL] [Abstract][Full Text] [Related]
8. Systemic expression of inflammatory mediators in patients with chronic rhinosinusitis and nasal polyps with and without Aspirin Exacerbated Respiratory Disease.
Pezato R; Świerczyńska-Krępa M; Niżankowska-Mogilnicka E; Holtappels G; De Ruyck N; Sanak M; Derycke L; Van Crombruggen K; Bachert C; Pérez-Novo CA
Cytokine; 2016 Jan; 77():157-67. PubMed ID: 26615369
[TBL] [Abstract][Full Text] [Related]
9. Platelet activation markers overexpressed specifically in patients with aspirin-exacerbated respiratory disease.
Mitsui C; Kajiwara K; Hayashi H; Ito J; Mita H; Ono E; Higashi N; Fukutomi Y; Sekiya K; Tsuburai T; Akiyama K; Yamamoto K; Taniguchi M
J Allergy Clin Immunol; 2016 Feb; 137(2):400-11. PubMed ID: 26194538
[TBL] [Abstract][Full Text] [Related]
10. Urinary leukotriene E4 after lysine-aspirin inhalation in asthmatic subjects.
Christie PE; Tagari P; Ford-Hutchinson AW; Black C; Markendorf A; Schmitz-Schumann M; Lee TH
Am Rev Respir Dis; 1992 Dec; 146(6):1531-4. PubMed ID: 1333741
[TBL] [Abstract][Full Text] [Related]
11. Urinary LTE4 is higher after nasal provocation test with L-ASA in bronchial than in only nasal responders.
Micheletto C; Visconti M; Tognella S; Trevisan F; Dal Negro RW
Eur Ann Allergy Clin Immunol; 2007 May; 39(5):162-6. PubMed ID: 17626331
[TBL] [Abstract][Full Text] [Related]
12. Changes in urinary LTE4 and nasal functions following nasal provocation test with ASA in ASA-tolerant and -intolerant asthmatics.
Micheletto C; Tognella S; Visconti M; Trevisan F; Dal Negro RW
Respir Med; 2006 Dec; 100(12):2144-50. PubMed ID: 16678396
[TBL] [Abstract][Full Text] [Related]
13. On the role of PGD2 metabolites as markers of mast cell activation in asthma.
O'Sullivan S
Acta Physiol Scand Suppl; 1999 Apr; 644():1-74. PubMed ID: 10352758
[TBL] [Abstract][Full Text] [Related]
14. Cysteinyl leukotrienes overproduction and mast cell activation in aspirin-provoked bronchospasm in asthma.
Sladek K; Szczeklik A
Eur Respir J; 1993 Mar; 6(3):391-9. PubMed ID: 8386106
[TBL] [Abstract][Full Text] [Related]
15. Prostaglandin E2 systemic production in patients with asthma with and without aspirin hypersensitivity.
Mastalerz L; Sanak M; Gawlewicz-Mroczka A; Gielicz A; Cmiel A; Szczeklik A
Thorax; 2008 Jan; 63(1):27-34. PubMed ID: 17584993
[TBL] [Abstract][Full Text] [Related]
16. The leukotriene-receptor antagonist MK-0679 blocks airway obstruction induced by inhaled lysine-aspirin in aspirin-sensitive asthmatics.
Dahlén B; Kumlin M; Margolskee DJ; Larsson C; Blomqvist H; Williams VC; Zetterström O; Dahlén SE
Eur Respir J; 1993 Jul; 6(7):1018-26. PubMed ID: 8396534
[TBL] [Abstract][Full Text] [Related]
17. Possible involvement of mast-cell activation in aspirin provocation of aspirin-induced asthma.
Mita H; Endoh S; Kudoh M; Kawagishi Y; Kobayashi M; Taniguchi M; Akiyama K
Allergy; 2001 Nov; 56(11):1061-7. PubMed ID: 11703219
[TBL] [Abstract][Full Text] [Related]
18. Occupational asthma follow-up--which markers are elevated in exhaled breath condensate and plasma?
Pelclová D; Fenclová Z; Vlčková S; Klusáčková P; Lebedová J; Syslová K; Běláček J; Kuzma M; Navrátil T; Zakharov S; Kačer P
Int J Occup Med Environ Health; 2014 Apr; 27(2):206-15. PubMed ID: 24643743
[TBL] [Abstract][Full Text] [Related]
19. Oral and bronchial provocation tests with aspirin for diagnosis of aspirin-induced asthma.
Nizankowska E; Bestyńska-Krypel A; Cmiel A; Szczeklik A
Eur Respir J; 2000 May; 15(5):863-9. PubMed ID: 10853850
[TBL] [Abstract][Full Text] [Related]
20. Safety of parecoxib in asthmatic patients with aspirin-exacerbated respiratory disease.
Valero A; Sánchez-López J; Bartra J; Serrano C; Muñoz-Cano R; Roca J; Picado C
Int Arch Allergy Immunol; 2011; 156(2):221-3. PubMed ID: 21597303
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
